Skip to main content

Original articles AMEC 2021-2022

Krug J, Rodrian G, Petter K, Yang H, Khoziainova S, Guo W, Bénard A, Merkel S, Gellert S, Maschauer S, Spermann M, Waldner M, Bailey P, Pilarsky C, Liebl A, Tripal P, Christoph J, Naschberger E, Croner R, Schellerer VS, Becker C, Hartmann A, Tüting T, Prante O, Grützmann R, Grivennikov SI, Stürzl M, Britzen-Laurent N. N-glycosylation regulates intrinsic IFN-γ resistance in colorectal cancer: implications for immunotherapy. Gastroenterology. 2022 Nov 16:S0016-5085(22)01294-X. doi: 10.1053/j.gastro.2022.11.018. Online ahead of print.

Gamez-Belmonte R, Mahapatro M, Erkert L, Gonzalez-Acera M, Naschberger E, Yu Y, Tena-Garitaonaindia M, Patankar JV, Wagner Y, Podstawa E, Schödel L, Bubeck M, Neurath MF, Stürzl M, Becker C. Epithelial presenilin-1 drives colorectal tumour growth by controlling EGFR-COX2 signalling. Gut. 2022 Oct 19:gutjnl-2022-327323. doi: 10.1136/gutjnl-2022-327323. Online ahead of print. PMID: 36261293

Ammon A, Mellenthin L, Emmerich C, Naschberger E, Stürzl M, Mackensen A, Müller F. Reduced cytotoxicity by mutation of lysine 590 of Pseudomonas exotoxin can be restored in an optimized, lysine-free immunotoxin. Immunother Adv. 2022 Feb 21;2(1):ltac007. doi: 10.1093/immadv/ltac007. eCollection 2022.

Busenhart P,  Montalban-Arques A, Katkeviciute E, Morsy Y, Van Passen C, Hering L, Atrott K, Lang S, Garzon JFG, Naschberger E, Hartmann A, Rogler G, Stürzl M, Spalinger MR, Scharl M. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. J Immunother Cancer. 2022 Feb;10(2):e003465. doi: 10.1136/jitc-2021-003465.

Yu YQ, Thonn V, Patankar JV, Thoma OM, Waldner M, Zielinska M, Bao LL, Gonzalez-Acera M, Wallmüller S, Engel FB, Stürzl M, Neurath MF, Liebing E, Becker C. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth. Cell Death Dis. 2022 Jan 12;13(1):52. doi: 10.1038/s41419-021-04483-0.

Stehr AM, Wang G, Demmler R, Stemmler MP, Krug J, Tripal P, Schmid B, Geppert CI, Hartmann A, Muñoz LE, Schoen J, Völkl S, Merkel S, Becker C, Schett G, Grützmann R, Naschberger E, Herrmann M, Stürzl M. Neutrophil extracellular traps drive epithelial-mesenchymal transition of human colon cancer. Inflamm Bowel Dis. 2021 Aug 19;27(9):1491-1502. doi: 10.1093/ibd/izaa346.

Stürzl M, Kunz M, Krug SM, Naschberger E. Angiocrine regulation of epithelial barrier integrity in inflammatory bowel disease. Front Med (Lausanne). 2021 Aug 2;8:643607. doi: 10.3389/fmed.2021.643607. eCollection 2021. Review.

Ackermann M, Anders HJ, Bilyy R, Bowlin GL, Daniel C, De Lorenzo R, Egeblad M, Henneck T, Hidalgo A, Hoffmann M, Hohberger B, Kanthi Y, Kaplan MJ, Knight JS, Knopf J, Kolaczkowska E, Kubes P, Leppkes M, Mahajan A, Manfredi AA, Maueröder C, Maugeri N, Mitroulis I, Muñoz LE, Narasaraju T, Naschberger E, Neeli I, Ng LG, Radic MZ, Ritis K, Rovere-Querini P, Schapher M, Schauer C, Simon HU, Singh J, Skendros P, Stark K, Stürzl M, van der Vlag J, Vandenabeele P, Vitkov L, von Köckritz-Blickwede M, Yanginlar C, Yousefi S, Zarbock A, Schett G, Herrmann M. Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ. 2021 Nov;28(11):3125-3139. doi: 10.1038/s41418-021-00805-z. Epub 2021 May 24.

Regensburger D, Tenkerian C, Pürzer V, Schmid B, Wohlfahrt T, Stolzer I, López-Posadas R, Günther C, Waldner MJ, Becker C, Sticht H, Petter K, Flierl C, Gass T, Thoenissen T, Geppert C, Britzen-Laurent N, Méniel VS, Ramming A, Stürzl M, Naschberger E. Matricellular protein SPARCL1 regulates blood vessel integrity and antagonizes inflammatory bowel disease. Inflamm Bowel Dis. 2021 Aug 19;27(9):1491-1502. doi: 10.1093/ibd/izaa346.

Katkeviciute E, Hering L, Montalban-Arques A, Busenhart P, Schwarzfischer M, Manzini R, Conde J, Atrott K, Lang S, Rogler G, Naschberger E, Schellerer VS, Stürzl M, Rickenbacher A, Turina M, Weber A, Leibl S, Leventhal GE, Levesque M, Boyman O, Scharl M, Spalinger MR. Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development. J Clin Invest. 2021 Jan 4;131(1):e140281. doi: 10.1172/JCI140281.